13th Oct 2021 18:01
13 October 2021
CVS Group Plc
("CVS", the "Company" or the "Group")
Exercise of Options, PDMR Dealing and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services, announces that on 13 October 2021, options over a total of 97,491 new ordinary shares of 0.2 pence each (the "New Shares") were exercised under the CVS Group Long Term Incentive Plan (LTIP) 12 (2018/2021), at an exercise price of 0.2 pence.
Richard Fairman, Chief Executive Officer, and Ben Jacklin, Chief Operating Officer, exercised options over 30,969 and 6,194 ordinary shares of 0.2p each in the Company respectively ("Ordinary Shares"). The balance of the options were exercised by certain other employees and former employees of the Company.
On 13 October 2021, the Company was notified that, on that date, Richard Fairman and Ben Jacklin sold 14,601 and 2,921 Ordinary Shares respectively at a price of £24.2215 per Ordinary Share. These sale amounts are sufficient to meet the costs of exercise incurred by the PDMR option holders, including personal taxation.
Following their respective option exercises and their sales of a portion of the new shares arising, Richard Fairman holds a beneficial interest in 27,818 Ordinary Shares in the Company, representing approximately 0.039 per cent of the total voting rights of the Company following the issue of the New Shares, and Ben Jacklin holds a beneficial interest in 4,709 Ordinary Shares in the Company, representing approximately 0.007 per cent of the total voting rights of the Company, calculated on the same basis.
Application has been made for the New Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, to be admitted to trading on AIM which is expected to occur on Tuesday 19 October, 2021.
Following the issue of the New Shares, the Company has a total issued share capital of 70,866,133 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the New Shares, the total number of voting rights in the Company will be 70,866,133. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
This announcement is released by CVS Group plc and contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"), encompassing information relating to trading for the Company's current financial year, and is disclosed in accordance with the Company's obligations under UK MAR. This announcement is being made on behalf of the Company by the director named below.
Contacts: | |
CVS Group plc | via MHP Communications |
Richard Fairman, CEO | |
Jenny Farrer, Company Secretary | |
Singer Capital Markets (Nominated Adviser & Broker) | +44 20 7496 3000 |
Aubrey Powell / Jen Boorer / Rachel Hayes |
|
MHP Communications (Financial PR) | +44 20 3128 8549 |
Andrew Jaques / Rachel Mann / Charles Hirst |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Richard Fairman
| ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| CVS Group plc | ||||
b)
| LEI
| 213800J41XDQ2NX48O05 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 0.2 pence each
GB00B2863827
| ||||
b)
| Nature of the transaction
| i) Exercise of options under LTIP 12 ii) Partial sale of ordinary shares arising from exercise | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
| N/A
| ||||
e)
| Date of the transaction
| 13 October 2021 | ||||
f)
| Place of the transaction
| London Stock Exchange | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Ben Jacklin | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Operating Officer | ||||
b)
| Initial notification /Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| CVS Group plc | ||||
b)
| LEI
| 213800J41XDQ2NX48O05 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 0.2 pence each
GB00B2863827
| ||||
b)
| Nature of the transaction
| i) Exercise of options under LTIP 12 ii) Partial sale of ordinary shares arising from exercise | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
| N/A
| ||||
e)
| Date of the transaction
| 13 October 2021 | ||||
f)
| Place of the transaction
| London Stock Exchange | ||||
Related Shares:
CVS Group